Next Article in Journal
Thinking Outside the Box: Utilizing Nontraditional Animal Models for COVID-19 Research
Previous Article in Journal / Special Issue
Serum Metabolic Profiling Identifies Key Differences between Patients with Single-Ventricle Heart Disease and Healthy Controls
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJTM
Volume 2
Issue 1
10.3390/ijtm2010009
Review Report
ijtm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

A Multimodal Omics Exploration of the Motor and Non-Motor Symptoms of Parkinson’s Disease

Int. J. Transl. Med. 2022, 2(1), 97-112; https://doi.org/10.3390/ijtm2010009
by François-Xavier Lejeune 1,2,†, Farid Ichou 3,†, Etienne Camenen 1,2,†, Benoit Colsch 4, Florence Mauger 5, Caroline Peltier 1,2, Ivan Moszer 1,2, Emmanuel Gilson 1,2, Morgane Pierre-Jean 5, Edith Le Floch 5, Victor Sabarly 6, Arthur Tenenhaus 7, Jean-François Deleuze 5, Claire Ewenczyk 1,8, Marie Vidailhet 1,9 and Fanny Mochel 1,8,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Transl. Med. 2022, 2(1), 97-112; https://doi.org/10.3390/ijtm2010009
Submission received: 17 December 2021 / Revised: 21 February 2022 / Accepted: 4 March 2022 / Published: 8 March 2022
(This article belongs to the Special Issue Biomarker Discovery in Medical and Health Contexts Using Metabolomics)

Round 1

Reviewer 1 Report

The study by Lejeune et al. was undertaken to determine associations between lipidomics and transcriptomics and clinical scores based on motor, cognitive and emotional symptoms in 48 PD patients. It aimed to select “the most relevant candidate markers in the omics data to explain a phenotypic (clinical) trait of interest” however, the study design is not fully adequate for the research question.

First, the analysis does not cover the influence of antiparkinsonian drugs, which can affect clinical scores and metabolomics, as the PD patients are not divided into ON and OFF. Moreover, the potential clinical significance of the selected markers candidates is limited due to the lack of control individuals.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Description:

Authors used data form the previous clinical study Nucleipark patient cohort and grouped individuals into three clinical classes indicating either i) impaired postural control, combined with rapid eye movement sleep behavior disorder (RBD), ii) impaired postural control without RBD, iii) the presence of RBD without impaired postural control.

Such cohort division was used in previous studies to identify imaging markers and brain regions associated with  patient’s clinical features.

Here authors correlated extensive data form transcriptomics, lipidomics and metabolomics in patients with complete 3 data sets.

Unfortunately in this study the  differential  analyses  of omics  data  conducted  with such divided clinical groups  did  not identify discriminating  variables.

General Remarks

  1. The text is well written with proficient language style and grammar.
  2. I am not qualified to judge the methodology and statistical part of this study. The analysis design is complicated. The idea of motor, cognitive and emotional models is not clear.
  3. Transcriptomics was performed on cells from blood. Please clearly indicate on what samples (plasma?) lipidomic and metabolomic studies were performed.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

N/A

Back to TopTop